HEPA vs ELVN

Analysts rate Enliven Therapeutics, Inc.

(ELVN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Enliven Therapeutics, Inc.

(ELVN) delivered a total return of +38. 9%, compared to -100. 0% for Hepion Pharmaceuticals, Inc. (HEPA). Over 10 years, the gap is even starker: ELVN returned -32. 9% versus HEPA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hepion Pharmaceuticals, Inc.

(HEPA) is the lower-risk stock at -0. 69β versus Enliven Therapeutics, Inc. 's 1. 27β — meaning ELVN is approximately -285% more volatile than HEPA relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Hepion Pharmaceuticals, Inc.

grew EPS 99. 2% year-over-year, compared to 3. 2% for Enliven Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hepion Pharmaceuticals, Inc.

(HEPA) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Enliven Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HEPA leads at 0. 0% versus 0. 0% for ELVN. At the gross margin level — before operating expenses — HEPA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hepion Pharmaceuticals, Inc.

(HEPA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 69)). Both have compounded well over 10 years (HEPA: -100. 0%, ELVN: -32. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.